Peter R. Dottino, MD
Researchers must begin investigating more of the molecular phases of ovarian cancer in an effort to better understand and predict disease recurrence, according to Peter Dottino, MD.
on Treatment Options in Ovarian Cancer, Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discussed the utilization of molecular methods to identify ovarian cancer following treatment with chemotherapy, and how this type of research impacts the field going forward.
OncLive: What were the highlights of your presentation on ovarian cancer?
The information was on some of the molecular techniques that we have developed at Mount Sinai School of Medicine to be able to detect ovarian cancer after it has been treated with chemotherapy. What we did was go back into our biobank, which is approximately 10 years old, where we have preserved specimens and DNA from primary tumors and recurrent tumors, as well as second-look washings that were taken from patients at the time of laparoscopy.
... to read the full story